Lyka Labs Quarterly Results for Trading Insights
In Mar 2026, Lyka Labs (LYKALABS) reported revenue ₹29 Cr and net profit ₹-8 Cr — revenue -14.7% YoY. Check Lyka Labs networth to track the company's total market size over time.
LYKALABS Quarterly Results — Revenue, Profit & EPS Highlights
Lyka Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse LYKALABS shareholder distribution to track promoter, FII and institutional holdings.
- Revenue of ₹29 Cr in Mar 2026 (-32.6% vs Jun 2026, -14.7% vs Mar 2025)
- Net Profit of ₹-8 Cr in Mar 2026 (-500.0% vs Jun 2026, -500.0% vs Mar 2025)
- EBITDA of ₹-6 Cr in Mar 2026 (-220.0% vs Jun 2026)
- Operating Margin of -23.0% in Mar 2026 (-34.0pp vs Jun 2026)
- Earnings Per Share of ₹-2.10 in Mar 2026 (-468.4% vs Jun 2026)
Lyka Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
LYKALABS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 29 | 43 | 38 | 34 | 34 | -32.6% | -14.7% |
| Net Profit (₹ Cr) | -8 | 2 | -3 | 2 | 1 | - | - |
| EBITDA (₹ Cr) | -6 | 5 | -2 | 5 | 4 | - | - |
| EPS (₹) | -2.10 | 0.57 | -0.94 | 0.49 | 0.25 | - | - |
| Operating Margin (%) | -23.0% | 11.0% | -7.0% | 12.0% | 11.0% | - | - |
LYKALABS Share Price Trend — 1-Year Movement Across Quarterly Results
Lyka Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Lyka Labs stock price NSE.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
LYKALABS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Lyka Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1902.4 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.4 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8597.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4896.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 425.4 |
|
Cipla
Mar 2026 |
₹115,699.61 Cr | 1432.2 | 6,612 | 543 | -9.3% | - | 8.2% | 208.5 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1120.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.5 |
All amounts in ₹ Crores